The NFIB/CARM1 Partnership is a Therapeutic Target for Small Cell Lung Cancer

ABSTRACT: This project identified NFI family members as CARM1 substrates. NFIB was previously reported to play a critical role in the development of small cell lung cancer. We provided evidence that the arginine methylation of NFIB is required for its oncogenic function in small cell lung cancer.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell

DISEASE(S): Lung Small Cell Carcinoma,Cervix Carcinoma

SUBMITTER: Maria Person  

LAB HEAD: Mark T. Bedford

PROVIDER: PXD038237 | Pride | 2023-02-07

REPOSITORIES: Pride